Namely, their results with exome analysis of Melanoma patients treated with Ipilimumab, a CTLA4 inhibitor, suggest that somatic mutations in cancer genomes that lead to tetrapeptides similar to those found in common pathogens are more likely to elicit a response to the therapy than common somatic mutations. The gene discussed is CTLA4; the disease is cancer.